Show simple item record

dc.contributor.authorBrunt, AM
dc.contributor.authorWheatley, D
dc.contributor.authorYarnold, J
dc.contributor.authorSomaiah, N
dc.contributor.authorKelly, S
dc.contributor.authorHarnett, A
dc.contributor.authorColes, C
dc.contributor.authorGoodman, A
dc.contributor.authorBahl, A
dc.contributor.authorChurn, M
dc.contributor.authorZotova, R
dc.contributor.authorSydenham, M
dc.contributor.authorGriffin, CL
dc.contributor.authorMorden, JP
dc.contributor.authorBliss, JM
dc.contributor.authorFAST-Forward Trial Management Group
dc.date.accessioned2016-08-26T15:24:57Z
dc.date.issued2016-07
dc.identifier.citationRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016, 120 (1), pp. 114 - 118
dc.identifier.issn0167-8140
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/81
dc.identifier.eissn1879-0887
dc.identifier.doi10.1016/j.radonc.2016.02.027
dc.description.abstractBackground and purpose FAST-Forward is a phase 3 clinical trial testing a 1-week course of whole breast radiotherapy against the UK standard 3-week regimen after primary surgery for early breast cancer. Two acute skin toxicity substudies were undertaken to test the safety of the test schedules with respect to early skin reactions.Material and methods Patients were randomly allocated to 40Gy/15 fractions (F)/3-weeks, 27Gy/5F/1-week or 26Gy/5F/1-week. Acute breast skin reactions were graded using RTOG (first substudy) and CTCAE criteria v4.03 (second substudy) weekly during treatment and for 4weeks after treatment ended. Primary endpoint was the proportion of patients within each treatment group with grade ⩾3 toxicity (RTOG and CTCAE, respectively) at any time from the start of radiotherapy to 4weeks after completion.Results 190 and 162 patients were recruited. In the first substudy, evaluable patients with grade 3 RTOG toxicity were: 40Gy/15F 6/44 (13.6%); 27Gy/5F 5/51 (9.8%); 26Gy/5F 3/52 (5.8%). In the second substudy, evaluable patients with grade 3 CTCAE toxicity were: 40Gy/15F 0/43; 27Gy/5F 1/41 (2.4%); 26Gy/5F 0/53.Conclusions Acute breast skin reactions with two 1-week schedules of whole breast radiotherapy under test in FAST-Forward were mild.
dc.formatPrint-Electronic
dc.format.extent114 - 118
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectFAST-Forward Trial Management Group
dc.subjectBreast
dc.subjectSkin
dc.subjectHumans
dc.subjectBreast Neoplasms
dc.subjectRadiodermatitis
dc.subjectRadiation Injuries
dc.subjectRadiotherapy Dosage
dc.subjectFemale
dc.titleAcute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial.
dc.typeJournal Article
dcterms.dateAccepted2016-02-22
rioxxterms.versionofrecord10.1016/j.radonc.2016.02.027
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2016-07
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
pubs.issue1
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Breast Radiobiology
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Breast Radiobiology
pubs.publication-statusPublished
pubs.volume120
pubs.embargo.termsNo embargo
icr.researchteamClinical Trials & Statistics Uniten_US
icr.researchteamTranslational Breast Radiobiologyen_US
dc.contributor.icrauthorMorden, James Peteren
dc.contributor.icrauthorSydenham, Marken
dc.contributor.icrauthorBliss, Judithen
dc.contributor.icrauthorYarnold, Johnen
dc.contributor.icrauthorGriffin, Clareen
dc.contributor.icrauthorSomaiah, Navitaen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0